October 19, 2016 — Lawyers for dozens of people who experienced severe bleeding after taking the blood-thinning drug Eliquis have asked a panel of federal judges to centralize the lawsuits in one court.
The motion (PDF) was filed on October 13 with the U.S. Judicial Panel on Multidistrict Litigation (JPML).
At least 34 lawsuits have been filed in 13 district courts nationwide, all accusing Pfizer and Bristol-Myers Squibb of failing to warn about the risk of uncontrollable bleeding.
Eliquis (apixaban) belongs to a new class of blood-thinning drugs designed to replace warfarin. But unlike warfarin, which is de-activated with Vitamin K, Eliquis has no reversal agent. This could be a problem for patients who are injured or need emergency surgery.
Lawyers asked judges to consolidate all federal Eliquis lawsuits in a Multi-District Litigation (MDL) in the U.S. District Court for the Southern District of New York.
They said this location would be suitable because the defendants are headquartered in that district and approximately half of the lawsuits (16) are already filed in New York.
Centralizing a large number of lawsuits in an MDL can improve efficiency, avoid duplicative discovery, and prevent conflicting rulings. In most cases, lawyers pick a small number of cases for “bellwether” trials and use the outcomes to negotiate settlements.
Do I have an Eliquis Lawsuit?
The Schmidt Firm, PLLC is currently accepting Eliquis induced injury cases in all 50 states. If you or somebody you know has been diagnosed with uncontrollable bleeding, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.